Immutep - Encouraging LAG-3 combo data at SITC
Prima BioMed has changed its name to Immutep Limited following shareholder approval in November. It reported an encouraging 33% preliminary...
77 Views
Immutep - Encouraging LAG-3 combo data at SITC
Prima BioMed has changed its name to Immutep Limited following shareholder approval in November. It reported an encouraging 33% preliminary...
71 Views
Support for anti-LAG-3 and APC-activator combos
Data presented at the European Society for Medical Oncology (ESMO) congress by third parties has positive implications for Prima Biomed’s LAG3...
83 Views
Support for anti-LAG-3 and APC-activator combos
Data presented at the European Society for Medical Oncology (ESMO) congress by third parties has positive implications for Prima Biomed’s LAG3...
79 Views
Preliminary LAG-3 combo data in breast cancer
Preliminary efficacy data, which Prima BioMed presented at ASCO from the 15-patient, safety run-in phase of its AIPAC study, showed sustained...
159 Views